PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders

Cristina Tassorelli,¹ Pranav Gandhi,² Molly Duan,² Karen Carr,² Kandavadivu Umashankar,² Jonathan Stokes,² Grace Forde,³ Tanya Bilchik,⁴ Martina Martini*, Rashmi Halker Singh⁵ | ¹University of Pavia, Pavia, Italy; ²AbbVie, North Chicago, IL, USA; ³North American Partners in Pain Management, North New Hyde Park, NY, USA; ⁴Department of Neurology, Yale School of Medicine, New Haven, CT, USA; ⁵Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.

Background: The impact of atogepant, an oral calcitonin gene-related peptide receptor antagonist used for migraine prevention, was evaluated on participants reporting best possible quality of life (QoL) based on Migraine-Specific Quality of Life Questionnaire among responders and non-responders to Patient Global Impression of Change (PGIC).

Methods: ADVANCE, ELEVATE, and PROGRESS were phase 3, multicenter, randomised, double-blind, placebo-controlled, 12-week trials that included adults with episodic migraine (EM), EM with prior inadequate responses to 2-4 oral preventive treatments, and chronic migraine (CM), respectively. This post hoc analysis evaluated the proportion of participants who achieved a score of 100 for all 3 MSQv2.1 domain scores at Week 12 based on their PGIC response (responders and non-responders). PGIC is a 7-point single question scale measuring participants impression of change in migraine symptoms since first dose of treatment. MSQv2.1 is a 3-domain questionnaire composed of 14 items designed to assess how migraine limits social and work activities, prevents social and work activities, and emotions associated with migraine. A score of 100 indicates the best possible QoL, with less disruption from migraine.

Results: In PGIC responders, a higher proportion of EM participants treated with atogepant 60mg once daily achieved MSQv2.1 scores of 100 in all 3 domains compared with placebo [ADVANCE(P≤.05); ELEVATE(P≤.001)], and numerically higher proportion in CM atogepant-treated participants [PROGRESS(P≥.05)].

Conclusion: A greater proportion of atogepant-treated EM and CM participants who are PGIC responders reported best possible QoL with lower disruption from migraine, compared with placebo.

Note: This individual (Martina Martini) has been added to this publication author by-line, with the permission of the original authors, for the express purpose of conducting the presentation at a local congress or in a local language. She did not contribute to the content of the publication.